1 (626) 351-3700

Author name: khalid@cs2ksoftware.com

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. […]

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma Read More »

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

AlivaMab Mouse Is Next-Generation Antibody Drug Discovery Platform of Choice for Top Pharmas BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma Read More »

Spine Wave Announces the Commercial Launch of the True Position® Pivoting Spacer System

SHELTON, CT–(Marketwired – July 11, 2016) – Spine Wave, Inc. is committed to the commercialization of high-quality, innovative medical devices for the treatment of spinal disorders. Spine Wave’s commitment was demonstrated by its previously announced acquisition of rights in the True Position® Pivoting Spacer System from Atlas Spine on February 23, 2016. Since then, Spine

Spine Wave Announces the Commercial Launch of the True Position® Pivoting Spacer System Read More »

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment

IRVINE, Calif., June 21, 2016 /PRNewswire/ — AiVita Biomedical, a therapeutic development company focused on regenerative and curative medicines, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to begin a Phase II clinical study. The study will investigate the efficacy of AiVita’s novel immunotherapy

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment Read More »

AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development

IRVINE, Calif., June 10, 2016 /PRNewswire/ — AiVita Biomedical, a therapeutic development company focused on regenerative and curative medicines, today announced it has completed a $2 million Series A round of equity investment. The capital comes from California Technology Ventures (CTV), a Southern California venture capital firm that focuses its investments in the fields of

AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development Read More »

Gamevice iOS gaming controllers gain prime real estate at Apple retail stores

Apple has once again chosen to spotlight a third-party product with prime shelf space at its retail stores, partnering with Gamevice to push sales of its lineup of iOS-compatible gaming controllers. Starting Wednesday, June 15 – Gamevice’s attachable gaming pads for iPhone and iPad are now available in all Apple retail stores worldwide. In addition,

Gamevice iOS gaming controllers gain prime real estate at Apple retail stores Read More »

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

AlivaMab Mouse Emerging as Top Pharmas’ Next-Generation Antibody Drug Discovery Platform of Choice BURLINGAME, Calif.–(BUSINESS WIRE)– 2, 2016 – Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. The AlivaMab Mouse is a unique, next-generation transgenic mouse platform for human

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma Read More »

FDA Expands Label Indication for PleuraFlow to Reduce Retained Blood

FDA Expands Label Indication for PleuraFlow to Reduce Retained Blood | Business Wire ANAHEIM, Calif.–(BUSINESS WIRE)–ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted expanded Indications for Use of the company’s patented PleuraFlow® Active Clearance Technology® System. The PleuraFlow System is

FDA Expands Label Indication for PleuraFlow to Reduce Retained Blood Read More »

Scroll to Top